ZD6126
Jump to navigation
Jump to search
Template:Short description Template:Drugbox
ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine.[1] It has shown promising results on tumors in mice.[2]
A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing.[3] Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.[4]
ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.[5]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".